Sunstone Life Science Fund II portfolio company Orphazyme announced today that the first two patients have been dosed with arimoclomol in the Phase III ‘AIDNPC’ Niemann-Pick disease type C clinical trial programme.

The first two patients in the NPC-002 Interventional Study of the AIDNPC clinical programme were enrolled at the Rigshospitalet site in Copenhagen, Denmark, marking a key milestone in the development of a new treatment option for Niemann-Pick disease Type C (NP-C) patients.